Vanguard Group Inc Black Diamond Therapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,905,300 shares of BDTX stock, worth $9.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,905,300

Previous 1,947,093 2.15%

Holding current value

$9.11 Million

Previous $5.47 Million 76.55%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.67 - $5.74 $111,587 - $239,891	-41,793 Reduced 2.15%	1,905,300 $9.66 Million
Q4 2023 Feb 14, 2024	SELL	$1.77 - $3.03 $29,187 - $49,964	-16,490 Reduced 0.84%	1,947,093 $5.47 Million
Q3 2023 Nov 14, 2023	BUY	$2.87 - $4.99 $1.38 Million - $2.41 Million	482,198 Added 32.55%	1,963,583 $5.64 Million
Q2 2023 Aug 14, 2023	BUY	$1.43 - $6.18 $1.04 Million - $4.47 Million	723,800 Added 95.54%	1,481,385 $7.48 Million
Q4 2022 Feb 10, 2023	BUY	$1.28 - $2.51 $623 - $1,222	487 Added 0.06%	757,585 $1.36 Million

Q3 2022 Nov 14, 2022	BUY	$1.96 - $4.01 $180,596 - $369,485	92,141 Added 13.86%	757,098 $1.28 Million
Q2 2022 Aug 12, 2022	SELL	$1.5 - $3.63 $17,595 - $42,579	-11,730 Reduced 1.73%	664,957 $1.64 Million
Q1 2022 May 13, 2022	SELL	$2.66 - $5.61 $899,356 - $1.9 Million	-338,104 Reduced 33.32%	676,687 $1.88 Million
Q4 2021 Feb 14, 2022	SELL	$5.18 - $8.48 $440,465 - $721,071	-85,032 Reduced 7.73%	1,014,791 $5.41 Million
Q3 2021 Nov 12, 2021	SELL	$8.46 - $12.42 $3.9 Million - $5.72 Million	-460,636 Reduced 29.52%	1,099,823 $9.3 Million
Q2 2021 Aug 13, 2021	BUY	$12.19 - $28.17 $19 Million - $44 Million	1,560,459 New	1,560,459 $19 Million

Others Institutions Holding BDTX

# of Institutions

Shares Held

36.5M

Call Options Held

29.6K

Put Options Held

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $174M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Black Diamond Therapeutics, Inc. Transaction History